Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about GRML, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
GRML holds $57.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $8.6M/quarter from operations, an estimated runway of 20 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 23 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GRML files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Strategic EP, LLC | 5%+ holder (13G) | 6,687,472 | 45.13% | 2026-03-04 |
| Joseph Sinkule Chief Executive Officer, Director |
Insider | 6,346,700 | 42.83% | 2026-03-04 |
| AnorTech Inc. | 5%+ holder (13G) | 1,451,268 | 9.79% | 2026-11-06 |
| CHARDAN CAPITAL MARKETS LLC 10% owner |
Insider | 1,284,364 | 8.67% | 2024-06-28 |
| Samuel M Zentman Director · +60,000 options |
Insider | 1,086,440 | 7.33% | 2026-03-04 |
| Shalom Hirschman Director |
Insider | 908,873 | 6.13% | 2026-03-04 |
| Jon McGarity Director · +60,000 options |
Insider | 551,277 | 3.72% | 2026-07-20 |
| Davidson Kempner Capital Management LP | 5%+ holder (13G) | 400,410 | 2.70% | 2026-08-26 |
| Jason David Sawyer Director |
Insider | 240,000 | 1.62% | 2026-07-22 |
| Jeff LeBlanc Chief Financial Officer |
Insider | 110,406 | 0.75% | 2026-08-25 |
| Private Advisor Group, LLC | Institution (13F) | 94,875 | 0.64% | 2026-09-30 |
| UBS Group AG | Institution (13F) | 67,853 | 0.46% | 2026-09-30 |
Share count 14,819,209 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-10-01 filed 2026-10-05 |
El-Dada Riad Hussein |
Sale (S) | 3,500 | $9.35 | 0 |
| 2026-08-25 filed 2026-08-25 |
LeBlanc Jeff |
Purchase (P) | 14,000 | $9.72 | 110,406 |
| 2026-07-22 filed 2026-07-23 |
Sawyer Jason David |
Purchase (P) | 240,000 | $0.23 | 240,000 |
| 2026-07-20 filed 2026-07-20 |
McGarity Jon |
Purchase (P) | 140,000 | $0.18 | 551,277 |
| 2026-07-16 filed 2026-07-17 |
LeBlanc Jeff |
Purchase (P) | 1,400,000 | $0.18 | 4,820,342 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GRML and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →